# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wednesday saw 219 companies set new 52-week lows.
Tuesday's session saw 167 companies set new 52-week lows.
Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.
Updated 2022 Financial Guidance The following statements are based on Telesis Bio's current expectations for fiscal 2022. ...
Telesis Bio (NASDAQ:DNAY) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.48) b...
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenu...
Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufactur...
Codex DNA, Inc. (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to chan...